Tolerability of postexposure antiretroviral prophylaxis for occupational exposures to HIV

Drug Safety

Volumn 24, Issue 8, 2001, Pages 587-597

  Lee, L M ^a   Henderson, D K ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INDINAVIR; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; ZIDOVUDINE;

DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INSOMNIA; MYALGIA; OCCUPATIONAL EXPOSURE; PREGNANCY COMPLICATION; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; VERTIGO;

EID: 0034940153     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-200124080-00003     Document Type: Review

References (58)

1. Longitudinal assessment of the risk for occupational/nosocomial transmission of human immunodeficiency virus, type I in health care workers
2. Postexposure antiviral chemoprophylaxis following occupational exposure to the human immunodeficiency virus
3. Prophylactic zidovudine after occupational exposure to the human immunodeficiency virus: An interim analysis
4. Use of zidovudine following occupational exposure to human immunodeficiency virus
5. Arguments against the chemoprophylactic use of zidovudine following occupational exposure to the human immunodeficiency virus
6. Zidovudine after occupational exposure to HIV
7. HIV postexposure prophylaxis in the 21st century
8. Postexposure treatment of HIV - Taking some risks for safety's sake
9. Postexposure chemoprophylaxis for occupational exposures to the human immunodeficiency virus
10. Effectiveness of postinoculation (R)-9-(2-phosphonylmethoxypropyl) adenine treatment for prevention of persistent simian immunodeficiency virus SIVmne infection depends critically on timing of initiation and duration of treatment
11. Animal studies of prophylaxis
12. Prevention of simian immunodeficiency virus, SIVsm, or HIV-2 infection in cynomolgus monkeys by pre- and postexposure administration of BEA-005
13. Prevention of SIV infection in macaques by (R)-9-(2-phosphonylmethoxypropyl)adenine
14. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment: Pediatric AIDS Clinical Trials Group Protocol 076 Study Group
15. Impact of zidovudine post-perinatal exposure prophylaxis on vertical HIV-1 transmission: A prospective cohort study in four US cities
16. Abbreviated regimens of zidovudine prophylaxis and perinatal transmission of the human immunodeficiency virus
17. A case-control study of HIV seroconversion in health care workers after percutaneous exposure
18. Failure to develop HIV infection after receipt of HIV-contaminated blood and postexposure prophylaxis
19. Transient detection of plasma HIV-1 RNA during postexposure prophylaxis
20. Public Health Service statement on management of occupational exposure to human immunodeficiency virus, including considerations regarding zidovudine postexposure use
21. Update: Provisional Public Health Service recommendations for chemoprophylaxis after occupational exposure to HIV
22. Public Health Service guidelines for the management of health-care worker exposures to HIV and recommendations for postexposure prophylaxis
23. New guidance on post exposure prophylaxis of health care workers exposed to HIV at work
24. New guidelines on post exposure prophylaxis for HIV
25. Toxicity of antiretroviral agents
26. Hepatotoxicity and rash associated with zidovudine and zalcitabine chemoprophylaxis
27. Seizure associated with zidovudine
28. Early lipodystrophy occurring during postexposure prophylaxis
29. Occupational exposure to HIV: Experience at a tertiary care center
30. Toxicity of post-exposure prophylaxis for human immunodeficiency virus
31. Adverse effects associated with use of nevirapine in HIV postexposure prophylaxis for 2 health care workers
32. Serious adverse events attributed to nevirapine regimens for postexposure prophylaxis after HIV exposures - Worldwide, 1997-2000
33. Safety of zidovudine administered as post-exposure chemoprophylaxis to health-care workers sustaining HIV-related occupational exposures
34. Safety of zidovudine (ZDV) administered as post-exposure chemoprophylaxis to healthcare workers (HCW) after occupational exposures to HIV
35. Safety of zidovudine (AZT) administered as post-exposure chemoprophylaxis to healthcare workers (HCW) sustaining occupational exposures (OE) to HIV
36. Safety of zidovudine (AZT) administered as postexposure chemoprophylaxis to healthcare workers (HCW) sustaining occupational exposures (OE) to HIV
37. Zidovudine safety and tolerance among uninfected healthcare workers: A brief update
38. Post-exposure prophylaxis for human immunodeficiency virus at San Francisco General Hospital
39. HIV exposure risk assessment and prophylactic treatment
40. Post-exposure prophylaxis for HIV infection. Italian registry of post-exposure prophylaxis
41. Risk of hepatitis C seroconversion after occupational exposures in health care workers: Italian study group on occupational risk of HIV and other bloodborne infections
42. Update: Zidovudine postexposure prophylaxis in Italy
43. Zidovudine prophylaxis after accidental exposure to HIV: The Italian experience
44. Zidovudine in post-exposure prophylaxis of health-care workers
45. The Italian registry of antiretroviral prophylaxis: Zidovudine toxicity in uninfected healthcare workers
46. Tolerability, safety, and acceptability of zidovudine prophylaxis in health care workers
47. Zidovudine (AZT) use after occupational HIV exposure: Toxicity and failures reported to CDC
48. Side effects of AZT prophylaxis after occupational exposure to HIV-infected blood
49. Postexposure prophylaxis for human immunodeficiency virus: Frequency of initiation and completion of newly recommended regimen
50. Combination Post-Exposure Prophylaxis (PEP): A prospective study of HIV-Exposed Health Care Workers (HCW)
51. Experience of healthcare workers taking postexposure prophylaxis
52. Issues on antiretroviral post exposure combination prophylaxis
53. Postexposure prophylaxis after sexual or drug use exposure to HIV: Final results from the San Francisco Post Exposure Prevention Project
54. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-I in Kampala, Uganda: HIVNET 012 randomised trial
55. Zidovudine-lamivudine for prevention of mother to child HIV-1 transmission
56. Indinavir concentrations and St John's wort
57. Postexposure prophylaxis for occupational exposure to HIV